Janux Therapeutics Inc
JANX
Company Profile
Business description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Contact
10955 Vista Sorrento Parkway
Suite 200
San DiegoCA92130
USAT: +1 858 751-4493
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
109
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.70 | 9.80 | -0.11% |
| CAC 40 | 8,087.42 | 12.81 | 0.16% |
| DAX 40 | 23,693.71 | 17.15 | -0.07% |
| Dow JONES (US) | 47,882.90 | 408.44 | 0.86% |
| FTSE 100 | 9,692.07 | 9.73 | -0.10% |
| HKSE | 25,775.49 | 14.76 | 0.06% |
| NASDAQ | 23,454.09 | 40.42 | 0.17% |
| Nikkei 225 | 50,857.97 | 993.29 | 1.99% |
| NZX 50 Index | 13,515.62 | 66.92 | -0.49% |
| S&P 500 | 6,849.72 | 20.35 | 0.30% |
| S&P/ASX 200 | 8,618.40 | 0.40 | -0.00% |
| SSE Composite Index | 3,869.81 | 8.19 | -0.21% |